JPMorgan initiated coverage of Enanta (ENTA) with an Overweight rating and $17 price target The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the positive view. The viral infection has significant unmet need and the study showed faster symptom reduction in the overall population, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: